Revised guidelines for the diagnosis and control of tuberculosis: Impact on management in the elderly

Drugs and Aging

Volumn 22, Issue 8, 2005, Pages 663-686

  Van Den Brande, Paul ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM; ANTIDIABETIC AGENT; BACTERIAL DNA; BCG VACCINE; CARBAMAZEPINE; CORTICOSTEROID; CYCLOSPORIN A; DAPSONE; DIAZEPAM; DIGITALIS; ETHAMBUTOL; ISONIAZID; KETOCONAZOLE; METHADONE; ORAL CONTRACEPTIVE AGENT; PHENYTOIN; PREDNISOLONE; PROBENECID; PROTEINASE INHIBITOR; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; STREPTOMYCIN; THEOPHYLLINE; TUBERCULOSTATIC AGENT; WARFARIN;

ACID FAST BACTERIUM; ACUTE PSYCHOSIS; ARTHRALGIA; BACTERIAL TRANSMISSION; BACTERICIDAL ACTIVITY; BACTERIUM CULTURE; BACTERIUM DETECTION; BACTERIUM IDENTIFICATION; BCG VACCINATION; BYSTANDER EFFECT; CONCENTRATION RESPONSE; DIAGNOSTIC APPROACH ROUTE; DIGESTIVE SYSTEM FUNCTION DISORDER; DIZZINESS; DRUG ABSORPTION; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG ERUPTION; DRUG EXCRETION; DRUG FEVER; DRUG METABOLISM; EDUCATION PROGRAM; EXTRAPULMONARY TUBERCULOSIS; FIBEROPTIC BRONCHOSCOPY; FLU LIKE SYNDROME; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GERIATRIC PATIENT; HEALTH PROMOTION; HEPATITIS; HOSPITAL INFECTION; HUMAN; HYPERURICEMIA; INFECTION PREVENTION; INFECTION RATE; INSOMNIA; KIDNEY FAILURE; LIVER TOXICITY; LUNG LAVAGE; LUNG TUBERCULOSIS; MAXIMUM TOLERATED DOSE; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NEPHROTOXICITY; NEUROTOXICITY; NURSING HOME; OTOTOXICITY; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT MONITORING; PERIPHERAL NEUROPATHY; PHOTOSENSITIVITY; PRIORITY JOURNAL; QT PROLONGATION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVIEW; THROMBOCYTOPENIA; TRANSBRONCHIAL BIOPSY; TREATMENT FAILURE; VISUAL IMPAIRMENT;

ANTITUBERCULAR AGENTS; HUMANS; PRACTICE GUIDELINES; TUBERCULOSIS;

EID: 23744478669     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200522080-00004     Document Type: Review

References (102)

1. Herzog H. History of tuberculosis. Respiration 1998; 65: 5-15
2. Donoghue HD, Spigelman M, Greenblatt CL, et al. Tuberculosis: from prehistory to Robert Koch, as revealed by ancient DNA. Lancet Infect Dis 2004; 4: 584-92
3. Snider GL. Tuberculosis then and now: a personal perspective on the last 50 years. Ann Intern Med 1997; 126: 237-43
4. Rieder HL. Epidemiology of tuberculosis in Europe. Eur Respir J 1995; 20: 620s-32s
5. Young LS, Wormser GP. The resurgence of tuberculosis. Scand J Infect Dis 1994; 93: 9-19
6. Iseman MD. A clinician's guide to tuberculosis. Philadelphia (PA): Lippincott Williams and Wilkins, 2000
7. Lauzardo M, Ashkin D. Phthisiology at the dawn of the new century: a review of tuberculosis and the prospects for its elimination. Chest 2000; 117: 1455-73
8. Rose AM, Watson JM, Graham C, et al. Tuberculosis at the end of the 20th century in England and Wales: results of a national survey in 1998. Thorax 2001; 56: 173-9
9. Dye C, Scheele S, Dolin P, et al. Consensus statement: global burden of tuberculosis - estimated incidence, prevalence and mortality by country. WHO global surveillance and monitoring project. JAMA 1999; 282: 677-86
10. Van den Brande P, Vanhoenacker F, Demedts M. Tuberculosis at the beginning of the third millenium: one disease, three epidemics. Eur Radiol 2003; 13: 1767-70
11. Corbett EL, Watt CJ, Walker N, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003; 163: 1009-21
12. Davies PD. The effects of poverty and ageing on the increase in tuberculosis. Monaldi Arch Chest Dis 1999; 54: 168-71
13. Raviglione MC. The TB epidemic from 1992 to 2002. Tuberculosis 2003; 83: 4-14
14. Dolin PJ, Raviglione MC, Koch A. Estimates of future global tuberculosis morbidity and mortality. MMWR Morb Mortal Wkly Rep 1993; 42: 961-4
15. Van den Brande P, Uydebrouck M, et al. Tuberculosis in asylum seekers in Belgium. Eur Respir J 1997; 10: 610-4
16. Chaimowicz F. Age transition of tuberculosis incidence and mortality in Brazil. Rev Saude Publica 2001; 35: 81-7
17. Devereaux Hutton M, Cauthen GM, et al. Results of a 29-state survey of tuberculosis in nursing homes and correctional facilities. Public Health Rep 1993; 108: 305-14
18. Kearney MT, Wanklyn PD, Goldman JM. Urban deprivation and tuberculosis in the elderly. Respir Med 1994; 88: 703-4
19. Stead WW. Tuberculosis among elderly persons: an outbreak in a nursing home. Ann Intern Med 1981; 94: 606-10
20. Ijaz K, Dillaha JA, Yang Z, et al. Unrecognized tuberculosis in a nursing home causing death with spread of tuberculosis to the community. J Am Geriatr Soc 2002; 50: 1213-8
21. Van den Brande P, Demedts M. Four-stage tuberculin testing in elderly subjects induces age-dependent progressive boosting. Chest 1992; 101: 447-50
22. Ben-Yehuda A, Weksler ME. Host resistance and the immune system. Clin Geriatr Med 1992; 8: 701-11
23. Castle S, Uyemura K, Wong W, et al. Evidence of enhanced type 2 immune response and impaired upregulation of a type 1 response in frail elderly nursing home residents. Mech Ageing Dev 1997; 94: 7-16
24. Kurashima C, Utsuyama M, Kasi M, et al. The role of thymus in the aging of TH cell subpopulations and age-associated alteration of cytokine production by these cells. Int Immunol 1995;7: 97-104
25. Menzies D. Interpretation of repeated tuberculin tests: boosting, conversion and reversion. Am J Respir Crit Care Med 1999;159: 15-21
26. Finucane TE. The American Geriatrics Society Statement on two-step PPD testing for nursing home patients on admission. J Am Geriatr Soc 1988; 36: 77-8
27. Stead WW, Kerby GR, Schlueter DP, et al. The clinical spectrum of primary tuberculosis in adults. Ann Intern Med 1968;68: 731-45
28. Van den Brande P, Vijgen J, Demedts M. Clinical spectrum of pulmonary tuberculosis in older patients: comparison with younger patients. J Gerontol 1991; 46: M204-9
29. Miller RA. The aging immune system: primer and prospectus. Science 1996; 273: 70-4
30. Perez-Guzman C, Vargas MH, Torres-Cruz A, et al. Does aging modify pulmonary tuberculosis: a meta-analytical review. Chest 1999; 116: 961-7
31. Rajagopalan S. Tuberculosis and aging: a global health problem. Clin Infect Dis 2001; 33: 1034-9
32. Korzeniewska-Kosela M, Krysl J, Müller N, et al. Tuberculosis in young adults and the elderly. Chest 1994; 106: 28-32
33. Leung CC, Yew WW, Chan CK, et al. Tuberculosis in older people: a retrospective and comparative study from Hong Kong. J Am Geriatr Soc 2002; 50: 1219-26
34. American Thoracic Society. Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med 2000; 161: 1376-95
35. Rieder HL. How to combat tuberculosis in the year 2000? Respiration 1998; 65: 423-31
36. Patel YR, Mehta JB, Harvill L. Flexible bronchoscopy as a diagnostic tool in the evaluation of pulmonary tuberculosis in an elderly population. J Am Geriatr Soc 1993; 41: 629-32
37. Conde MB, Soares SL, Mello FC, et al. Comparison of sputum induction with fiberoptic bronchoscopy in the diagnosis of tuberculosis. Am J Respir Crit Care Med 2000; 162: 2238-40
38. Drobniewski FA, Caws M, Gibson A, et al. Modern laboratory diagnosis of tuberculosis. Lancet Infect Dis 2003; 3: 141-7
39. Lim TK, Zhu D, Gough A, et al. What is the optimal approach for using a direct amplification test in the routine diagnosis op pulmonary tuberculosis? A preliminary assessment. Respirology 2002; 7: 351-7
40. Van den Brande P, Verniest T, Verwerft J, et al. Impact of age and radiographic presentation on the presumptive diagnosis of tuberculosis. Respir Med 2002; 96: 979-83
41. American Thoracic Society. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167: 603-62
42. Migliori GB, Raviglione MC, Schaberg T, et al. Tuberculosis management in Europe: Task Force of the European Respiratory Society (ERS), the World Health Organisation (WHO) and the International Union against Tuberculosis and Lung Disease (IUATLD) Europe Region. Eur Respir J 1999; 14: 978-92
43. Pabloz-Méndez A, Sterling TR, Frieden TR. The relationship between delayed or incomplete treatment and all-cause mortality in patients with tuberculosis. JAMA 1996; 276: 1223-8
44. Rothe TB, Karrer W. Short-course therapy of pulmonary tuberculosis: doctor's compliance. Tuber Lung Dis 1996; 77: 93-7
45. Vlaamse Vereniging voor Respiratoire Gezondheiszorg en Tuberculosebestrijding. Tuberculoseregistratie en opsporing in 1994. Berichten 1995; 5: 3-10
46. Ormerod LP, Prescott RJ. The management of pulmonary and lymph node tuberculosis notified in England and Wales in 1998. Clin Med 2003; 3: 57-61
47. Oursler KK, Moore RD, Bishai WR, et al. Survival of patients with pulmonary tuberculosis: clinical and molecular epidemiologic factors. Clin Infect Dis 2002; 34: 752-9
48. Rajogopalan S, Yoshikawa TT. Tuberculosis in long-term-care facilities. Infect Control Hosp Epidemiol 2000; 21: 611-5
49. Frieden TR, Sterling TR, Munsiff SS, et al. Tuberculosis. Lancet 2003; 362: 887-99
50. Horsburgh Jr CR, Feldman S, Ridzon R. Practice guidelines for the treatment of tuberculosis. Clin Infect Dis 2000; 31: 633-9
51. Grosset J. Bacteriologic basis of short-course chemotherapy for tuberculosis. Clin Chest Med 1980; 1: 231-41
52. Jindani A, Doré CJ, Mitchison DA. Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. Am J Respir Crit Care med 2003; 167: 1348-54
53. Zhang Y, Mitchison D. The curious characteristics of pyrazinamide: a review. Int J Tuberc Lung Dis 2003; 7: 6-21
54. Douglas JG, McLeod M-J. Pharmacokinetic factors in the modern drug treatment of tuberculosis. Clin Pharmacokinet 1999;37: 127-46
55. Joint Tuberculosis Committee of the British Thoracic Society. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Thorax 1998; 53: 536-48
56. Turnheim K. When drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderly. Exp Gerontol 2003; 38:843-53
57. Acocella G, Nonis A, Gialdroni-Grassi G, et al. Comparative bioavailability of isoniazid, rifampicin and pyrazinamide in free combination and in a fixed triple formulation designed for daily use in antituberculosis chemotherapy. Am Rev Respir Dis 1988; 136: 882-5
58. Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 2002; 62: 2169-83
59. Parkin DP, Vandenplas S, Botha FJ, et al. Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis. Am J Respir Crit Care Med 1997; 155: 1717-22
60. Pea F, Milaneschi R, Baraldo M, et al. Isoniazid and its hydrazine metabolite in patients with tuberculosis. Clin Drug Invest 1999; 17: 145-54
61. Sbarbaro JA, Iseman MD, Crowle AJ. The combined effect of rifampin and pyrazinamide within the human macrophage. Am Rev Respir Dis 1992; 146: 1448-51
62. Jain A, Mehta VL, Kulshrestha S. Effect of pyrazinamide on rifampicin kinetics in patients with tuberculosis. Tuber Lung Dis 1993; 74: 87-90
63. Plets MW, De Roux A, Roth A, et al. Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study. Antimicrob Agents Chemother 2004; 48: 780-2
64. Ginsburg AS, Grosset JH, Bishai WR. Fluoroquinolones, tuberculosis and resistance. Lancet Infect Dis 2003; 3: 432-42
65. Pablos-Méndez A, Knirsch CA, Barr RG, et al. Nonadherence in tuberculosis treatment: predictors and consequences in New York City. Am J Med 1997; 102: 164-70
66. Kimerling M. Low serum antimycobacterial drug levels in non-HIV-infected tuberculosis patients. Chest 1998; 113: 1178-83
67. Iseman MD, Cohn DL, Sbarbaro JA. Directly observed treatment of tuberculosis: we can't afford not to try it. N Engl J Med 1993; 328: 576-8
68. Weis SE, Slocum PC, Blais FX, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 1994; 330: 1179-84
69. Goble M, Iseman MD, Madsen LA, et al. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993; 328: 527-9
70. Burman WJ, Cohn DL, Rietmeijer CA, et al. Noncompliance with directly observed therapy for tuberculosis: epidemiology and effect on the outcome of treatment. Chest 1997; 111: 1168-73
71. Geerligs WA, Van Altena R, De Lange WCM, et al. Multidrug-resistant tuberculosis: long-term treatment outcome in the Netherlands. Int J Tuberc Lung Dis 2000; 4: 758-64
72. Colebunders R, Bastian I. A review of the diagnosis and treatment of smear-negative pulmonary tuberculosis. Int J Tuberc Lung Dis 2000; 4: 97-107
73. Dutt AK, Moers D, Stead WW. Smear-and culture-negative pulmonary tuberculosis: four-month short-course chemotherapy. Am Rev Respir Dis 1989; 139: 867-70
74. Van den Brande P, Demedts M. Empiric anti-tuberculous treatment of smear-negative pulmonary tuberculosis in elderly patients [abstract]. S Afr Respir J 2000; 6: 108
75. Small PM, Fujiwara PI. Management of tuberculosis in the United States. N Engl J Med 2001; 345: 189-200
76. Telzak EE, Fazal BA, Pollard CL, et al. Factors influencing time to sputum conversion among patients with smear-positive pulmonary tuberculosis. Clin Infect Dis 1997; 25: 666-70
77. Morris CD. The duration of excretion of viable bacilli in elderly patients on treatment for cavitating pulmonary tuberculosis. South Afr Med J 1996; 86: 958-60
78. Narita M, Hisada M, Thimmappa B, et al. Tuberculosis recurrence: multivariate analysis of serum levels of tuberculosis drugs, human immunodeficiency virus status, and other risk factors. Clin Infect Dis 2001; 32: 515-7
79. Yee D, Valiquette C, Pelletier M, et al. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003; 167: 1472-7
80. Van den Brande P, Van Steenbergen W, Vervoort G, et al. Aging and hepatotoxicity of isoniazid and rifampin in pulmonary tuberculosis. Am J Respir Crit Care Med 1995; 152: 1705-8
81. American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000; 161: S221-47
82. Jasmer RM, Nahid P, Hopewell PC. Latent tuberculosis infection. N Engl J Med 2002; 347: 1860-6
83. Nadal D. Is the in vitro Interferon-γ release assay an adequate replacement for the tuberculin skin test? Clin Infect Dis 2002; 34: 1457-9
84. Joint Tuberculosis Committee of the British Thoracic Society. Control and prevention of tuberculosis in the United Kingdom: code of practice 2000. Thorax 2000; 55: 887-901
85. Stevens JP, Daniel TM. Chemoprophylaxis of multidrug-resistant tuberculous infection in HIV uninfected individuals using ciprofloxacin and pyrazinamide: a decision analysis. Chest 1995; 108: 712-7
86. Gardam MA, Keystone EC, Menzies R, et al. Anti-tumor necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003; 3: 148-55
87. Stead WW, To T, Harrison RW, et al. Benefit-risk considerations in preventive treatment for tuberculosis in elderly persons. Ann Intern Med 1987; 107: 843-5
88. Rose DN, Schechter CB, Silver AL. The age threshold for isoniazid chemoprophylaxis: a decision analysis for low-risk tuberculin reactors. JAMA 1986; 256: 2709-13
89. Sorresoo DJ, Metha JB, Harvill LM, et al. Underutilization of isoniazid chemoprophylaxis in tuberculosis contacts 50 years of age and older: a prospective analysis. Chest 1995; 108:706-11
90. Segal-Maurer S, Kalkut GE. Environmental control of tuberculosis: continuing controversy. Clin Infect Dis 1994; 19:299-308
91. Centers for Disease Control and Prevention. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care facilities. MMWR Morb Mortal Wkly Rep 1994;43 (RR13): 1-132
92. LoBue PA, Catanzaro A. Effectiveness of a nosocomial tuberculosis control program at an urban teaching hospital. Chest 1998; 113: 1184-9
93. Centers for Disease Control and Prevention. Prevention and control of tuberculosis in facilities providing long-term care to the elderly. MMWR Morb Mortal Wkly Rep 1990; 39 (RR10):7-20
94. Marchand R, Tousignant P, Chang H. Cost-effectiveness of screening compared to case-finding approaches to tuberculosis in long-term care facilities for the elderly. Int J Epidemiol 1999; 28: 563-70
95. Stead WW. Management of health care workers after inadvertent exposure to tuberculosis: a guide for the use of preventive therapy. Ann Intern Med 1995; 122: 906-12
96. Stevens JP, Daniel TM. Bacille Calmette Guérin immunisation of health care workers exposed to multidrug-resistant tuberculosis: a decision analysis. Tuber Lung Dis 1996; 77: 315-21
97. International Union Against Tuberculosis and Lung Disease. Criteria for discontinuation of vaccination programs using Bacille Calmette-Guérin (BCG) in countries with a low prevalence of tuberculosis. Tuber Lung Dis 1994; 75: 179-80
98. Dye C, Garnett GP, Sleeman K, et al. Prospects for worldwide tuberculosis control under the WHO DOTS strategy: directly observed short-course therapy. Lancet 1998; 352: 1886-91
99. Citron KM. BCG vaccination against tuberculosis: international perspectives. BMJ 1993; 306: 222-3
100. Tascon RE, Colston MJ, Ragno S, et al. Vaccination against tuberculosis by DNA injection. Nat Med 1996; 2: 888-92
101. Stanford JL. Immunotherapy with Mycobacterium vaccae in the treatment of mycobacterial disease. J Infect 1999; 39: 179-82
102. Barnes PF. Immunotherapy for tuberculosis: wave of the future or tilting at windmills? Am J Respir Crit Care Med 2003; 168:142-3